GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Net Income

Pet Pharm Biotech Co (ROCO:7762) Net Income : NT$14.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Pet Pharm Biotech Co's Net Income for the six months ended in Dec. 2024 was NT$11.1 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was NT$14.5 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Pet Pharm Biotech Co's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was NT$0.27.


Pet Pharm Biotech Co Net Income Historical Data

The historical data trend for Pet Pharm Biotech Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Net Income Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24
Net Income
-3.81 9.15 14.51

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Net Income - 4.87 4.28 3.37 11.14

Pet Pharm Biotech Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Pet Pharm Biotech Co's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=12.419+2.086+0+0
=14.5

Pet Pharm Biotech Co's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=9.054+2.086+0+0
=11.1

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$14.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pet Pharm Biotech Co  (ROCO:7762) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Pet Pharm Biotech Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Pet Pharm Biotech Co Net Income Related Terms

Thank you for viewing the detailed overview of Pet Pharm Biotech Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Pet Pharm Biotech Co Business Description

Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines